Has David Tabby received payments from drug or device companies?

Yes. Drug and device makers reported $47,060 in general payments to David Tabby across 116 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Tabby did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Tabby come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Tabby

Neurology · Merion Station, PANPI 1346292901

Payments from drug & device makers

$47,060in general payments, 2019–2025

Across 116 payments — averaging $405.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$14K
Sanofi$12K
Bristol Myers Squibb$9K
Biohaven Pharmaceuticals, Inc.$6K
Catalyst Pharmaceuticals, Inc.$5K
Eli Lilly$663
plus $661 from 7 others

$1,944in research payments, 2019–2025

Across 1 payment — averaging $1944.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$2K

What the payments were for

Consulting fees$8,58819%
Speaking & faculty fees$34,04273%
Travel & lodging$1,6924%
Food & beverage$1,7454%
Education$3311%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	63	$14,449
Sanofi	12	$11,752
Bristol Myers Squibb	7	$8,666
Biohaven Pharmaceuticals, Inc.	9	$6,292
Catalyst Pharmaceuticals, Inc.	9	$4,577
Eli Lilly	1	$663
Biogen	4	$226
Novartis	2	$118
Teva Pharmaceuticals USA, Inc.	1	$90
Genentech, Inc.	2	$90
AstraZeneca	2	$66
Supernus Pharmaceuticals, Inc.	3	$46
Jazz Pharmaceuticals Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

UBRELVY$13,620
AUBAGIO$11,564
Ozanimod$8,516
NURTEC ODT$6,238
FIRDAPSE$1,000
VYALEV$125
KESIMPTA$117
MAYZENT$117
TECFIDERA$107

How this compares

$47,060 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sumatriptan Succinate	17	$4,726
Ondansetron Hcl	13	$2,283
Lidocaine	12	$948
Clonazepam	15	$873
Oxycodone Hcl	28	$692
RizatriptanRizatriptan Benzoate	12	$443
Methadone Hcl	12	$321
Cyclobenzaprine Hcl	23	$242
Diazepam	13	$203
Alprazolam	23	$148
Donepezil Hcl	14	$92
Celecoxib	11	$68
Zolpidem Tartrate	21	$57
Azithromycin	14	$27

Paid to pharmacies, not to this prescriber.

Other neurology in Merion Station

David WeismanAbington$9.3M
Amit Bar-OrPhiladelphia$7.7M
Thomas LeistPhiladelphia$5.8M
Jan DrappatzPittsburgh$4M
Lauren ElmanPhiladelphia$3.3M
David IrwinPhiladelphia$2.5M
Paula ClemensPittsburgh$2.1M
Anoopum GuptaPittsburgh$2M
Daniel KremensPhiladelphia$1.9M
Frances JensenPhiladelphia$1.8M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →